#Covid antibody treatment uk

[covid-safer-hotties]

Also preserved on our archive

By Alex Croft

Lower levels of protective antibodies could leave the UK population vulnerable to a rapid spread of the XEC Covid variant

The new Covid XEC variant could spread rapidly through the population as many people have not been vaccinated in a long time, an expert has warned.

Scientists believe the XEC variant will become the dominant Covid strain over the next few months, with a few mutations which may help it spread through autumn.

The variant, which derived from the omicron variant, is likely to take off in the next few weeks as it spreads through Europe after being first detected in Berlin in June.

An immunologist has told the The Independent that due to “reduced levels of protective neutralising antibodies”, the XEC variant could sweep through the UK at a rapid rate.

Current NHS guidance states that the Covid vaccine will be offered to people over 65, pregnant women, people with health conditions or treatments which increases their risk of serious illness, and people in care homes.

Professor Sheena Cruickshank, an immunology expert at the University of Manchester, says protection may be lower for much of the population, after a long time without being vaccinated.

“Predicting the rate of infection is complex,” she said.

“We haven’t yet seen data on how good XEC is at ducking our antibodies, and in the absence of effective ventilation measures in buildings or masking in UK [the new variant] may thrive.

“The rate of spread depends on exposure but also how vulnerable a population is.

“Many are some way from last vaccines and may have reduced levels of protective neutralising antibodies if so.”

The government currently rolls out the vaccine throughout two annual programmes: the spring and autumn booster programmes.

Since 2023, the spring programme has been for all over-75s, immunosuppressed people and care workers. The autumn programme vaccinates for all over-65s.

Those with good health between 50 and 65 have not been included in the free vaccine programme since 2022.

There is no indication that any further restrictions will need to be introduced “at this stage”, says Prof Cruickshank.

But preventative measures are vital in further reducing the need for future restrictions.

Track and trace, good ventilation, masks in clinical settings and paid-for vaccines for those who aren’t eligible for a free booster, would all help secure the UK’s health security.

“We have learned from the inquiry so far what not to do,” Prof Cruickshank said.

“Hopefully they will look at that, and learn and consider measures like track and trace or ventilation etc, to reduce the risk of the country needing to shut down.”

[trendingreportz]

Multiple Sclerosis Drugs Market - Forecast(2024 - 2030)

Multiple Sclerosis Drugs Market Overview

The Multiple Sclerosis Drugs Market size is estimated to reach $31.3 billion by 2028, growing at a CAGR of 3.7% during the forecast period 2023-2028. Treatment of multiple sclerosis may involve immunosuppressants, immunomodulators and monoclonal antibodies. Interferons are disease-modifying drugs that assist in decreasing relapses in people enduring multiple sclerosis. Intramuscular injections are utilized when additional kinds of delivery techniques like oral, intravenous and subcutaneous are not suggested. As per a novel clinical trial in August 2022, an experimental antibody therapy for multiple sclerosis can reduce symptom flare-ups by half, as compared to standard treatment. Interferon beta-1a has been certified by the U.S. Food and Drug Administration (FDA) to treat relapsing forms of multiple sclerosis and it has been assessed in clinical trials for the treatment of COVID-19. According to the National Multiple Sclerosis Society, more than 2.8 million people are living with Multiple Sclerosis worldwide. The burgeoning focus of firms on pipeline products for multiple sclerosis is set to drive the Multiple Sclerosis Drugs Market. The recommended continuous medicines for multiple sclerosis-like interferons to decrease the requirement for hospitalization due to COVID-19 are set to propel the growth of the Multiple Sclerosis Drugs Industry during the forecast period 2023-2028. This represents the Multiple Sclerosis Drugs Industry Outlook.

Multiple Sclerosis Drugs Market Report Coverage

The “Multiple Sclerosis Drugs Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Multiple Sclerosis Drugs Market.

By Drug Class: Immunomodulators, Immunosuppressants, Interferons and Others.

By Route Of Administration:Oral, Injection (Intramuscular, Subcutaneous and Intravenous).

By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Request Sample

Key Takeaways

Geographically, North America (Multiple Sclerosis Drugs market share) accounted for the highest revenue share in 2022. It is poised to dominate the market over the period 2023-2028 owing to the increasing predominance of multiple sclerosis involving immunomodulators in the North American region.

The growth of the Multiple Sclerosis Drugs Market is being driven by considerable financing of large pharmaceutical firms in the drug development procedure and surging interferon treatment of Multiple Sclerosis. However, the soaring cost of medications is one of the major factors hampering the growth of the Multiple Sclerosis Drugs Market.

The Multiple Sclerosis Drugs Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Multiple Sclerosis Drugs Market report.

Multiple Sclerosis Drugs Market Segment Analysis - by Drug Class

The Multiple Sclerosis Drugs Market based on drug class can be further segmented into Immunomodulators, Immunosuppressants, Interferons and Others. The Immunomodulators Segment held the largest share of the Multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging application of immunomodulators for the treatment of multiple sclerosis and its connected symptoms. Interferon beta and glatiramer acetate (GA) were the earliest immunomodulators certified for the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. The greater prescription rates are further propelling the growth of the Immunomodulators segment.

Furthermore, the Immunosuppressants segment is estimated to grow at the fastest CAGR of 4.3% during the forecast period 2023-2028 owing to the typical application of immunosuppressants like azathioprine, cyclophosphamide, methotrexate and mitoxantrone for the treatment of Multiple Sclerosis as well as application of immunosuppressants as combination therapy or monotherapy.

Inquiry Before Buying

Multiple Sclerosis Drugs Market Segment Analysis - by Route Of Administration

The Multiple Sclerosis Drugs Market based on the route of administration can be further segmented into Oral, Subcutaneous and Injection. The Injection Segment held the largest share of the multiple Sclerosis Drugs market in 2022. This growth is fueled by the surging count of approvals for multiple sclerosis medications as injections for subcutaneous application in the treatment of ailment. The injection segment is sub-segmented into intramuscular, subcutaneous and intravenous. The increasing application of intravenous (IV) infusions like OCREVUS to treat relapsing or primary progressive forms of Multiple Sclerosis is further propelling the growth of this segment.

Furthermore, the Oral segment is estimated to grow at the fastest CAGR of 5.5% during the forecast period 2023-2028 due to the growing introduction of novel products, assistance in patient satisfaction, boosting therapeutic compliance and the soaring inclination toward oral medications.

Multiple Sclerosis Drugs Market Segment Analysis - by Geography

North America (Multiple Sclerosis Drugs Market) dominated the Multiple Sclerosis Drugs market with a 40% share of the overall market in 2022. The growth is driven by the existence of key players in the North American region. The approval by regulatory authorities is further propelling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook, in the North American region. Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fuelled by the factors like enhanced distribution networks of pharmaceutical firms in emerging economies in the Asia-Pacific region. The surging government initiatives are further fueling the progress of the Multiple Sclerosis Drugs Market in the Asia-Pacific region.

Schedule a Call

Multiple Sclerosis Drugs Market Drivers

Surging Approvals for Intramuscular Injections:

As per Healthline, current findings from the National MS Society estimate that almost 1 million people in the U.S. are living with Multiple Sclerosis. In February 2021, the U.S. Food and Drug Administration (FDA) certified an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat patients with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into the muscle, is what is usually utilized to convey the flu shot. As per Biogen, Plegridy’s developer, treatment provided through intramuscular injection is as efficient as the subcutaneous injection formulation. This novel formulation was also currently certified by the European Commission. The surging approvals for intramuscular injections are therefore fueling the growth of the Multiple Sclerosis Drugs Market during the forecast period 2023-2028.

Soaring Treatment Involving Immunomodulators and Immunosuppressants:

As per Healthline, a supposed 2.5 million people live with Multiple Sclerosis globally. Medications certified for application in multiple sclerosis that decrease the frequency of intensifications or gradual infirmity advancement are termed disease-modifying drugs (DMDs). These DMDs can be further categorized as immunomodulators or immunosuppressants. Teriflunomide is an oral immunomodulator that causes anti-inflammatory impacts by restricting dihydroorotate dehydrogenase, a mitochondrial enzyme included in pyrimidine synthesis. It is designated for relapsing forms of MS. The most typically utilized immunosuppressants in Multiple Sclerosis are azathioprine, cyclophosphamide, methotrexate and mitoxantrone. The soaring treatment involving immunomodulators and immunosuppressants is fueling the growth of the Multiple Sclerosis Drugs Industry, thereby contributing to the Multiple Sclerosis Drugs Industry Outlook during the forecast period 2023-2028.

Multiple Sclerosis Drugs Market Challenges

Side Effects of Interferons:

As per MS Discovery Forum, an approximated 200 novel cases are diagnosed every week in the U.S. Interferon beta (IFNbeta) decreases the relapse rate and activity as assessed by serial MRI scanning and ailment advancement of Multiple Sclerosis. Therapy with IFNbeta may be connected with numerous unfavorable reactions. Comparatively repeated side effects involve flu-like symptoms, transient laboratory abnormalities, menstrual ailments and raised spasticity. Dermal injection site reactions happen subsequent to subcutaneous application of IFNbeta-1b and IFNbeta-1a. Likely side effects of IFNbeta involve different autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia and depression. These issues are thus hampering the growth of the Multiple Sclerosis Drugs Market.

Buy Now

Multiple Sclerosis Drugs Industry Outlook

More focus on pipeline drugs for multiple sclerosis and emerging R&D financing in the pharmaceutical industry are key strategies adopted by players in the Multiple Sclerosis Drugs Market. The top 10 companies in the Multiple Sclerosis Drugs market are:

Bayer AG

Teva Pharmaceutical Industries Ltd.

Novartis AG

Sanofi Inc.

F. Hoffmann-La Roche Ltd.

Celgene Corporation

Acorda Therapeutics, Inc.

Biogen, Inc.

Actelion Pharmaceuticals Ltd. (Johnson & Johnson)

Merck Serono (Merger between EMD Serono and Merck KGaA)

Recent Developments

In October 2021, Novartis declared that it would introduce 41 abstracts at the upcoming 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The data being introduced covered an all-inclusive MS portfolio. This stressed the firm’s dedication in enhancing the quality of life for people residing with MS at all phases of the ailment.

In June 2021, Novartis marked a collaboration agreement and alternative to acquiring Cellerys. Cellerys is a Zurich-based startup, conducting research on a therapy to combat Multiple Sclerosis (MS). 

In January 2020, Novartis favorably finished the acquisition of The Medicines Company. This included a possibly first-in-class, investigational cholesterol-lowering therapy - inclisiran. The Medicines Company proposed the New Drug Application (NDA) for inclisiran to FDA in December 2019. 

[tamanna31]

Aptamers Market Share, Supply, Sales, Manufacturers, Competitor and Consumption 2023 to 2030

Aptamers Industry Overview

The global aptamers market size was valued at USD 1.94 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 24.54% from 2023 to 2030.

Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages include small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies; may fuel the R&D of novel aptamers, thereby driving market growth. Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Consequently, nucleic-acid based aptamers & peptide aptamers might be effective against treating COVID-19 infection. Thus, various initiatives are being undertaken by the government to boost the R&D of novel treatment for COVID-19. For instance, in September 2020, the Department of Community & Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of novel treatment for the COVID-19.

The aptamers based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-COV-2 & COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. Aptamex is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized, and an emerging diagnostic kit for healthcare.

Aptamers based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently, increasing demand for aptamer based diagnostic products. According to Cancer Research UK estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.

In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute in market growth by addressing the increased demand.

As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is only the U.S. FDA approved (2004) therapeutic aptamer available in the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention towards the development of novel aptamer based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with drug AMD. Thus, expected approval of this drug may boost the growth of the market over the period.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global structural biology & molecular modeling techniques market size was valued at USD 7.13 billion in 2023 and is projected to grow at a CAGR of 15.4% from 2024 to 2030.

• The global targeted DNA RNA sequencing market size was valued at USD 10.12 billion in 2023 and is projected to grow at a CAGR of 19.4% from 2024 to 2030.

Global Aptamers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the market trends in each of the sub-markets from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the aptamers market on the basis of type, application, and region.

Type Outlook (Revenue, USD Million; 2018 - 2030)

Nucleic Acid Aptamer

Peptide Aptamer

Application Outlook (Revenue, USD Million; 2018 - 2030)

Diagnostics

Therapeutics

Research & Development

Others

Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

Saudi Arabia

UAE

Kuwait

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics. Some of the prominent players in the global aptamers market include:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

[industryforecastnews]

U.S. Veterinary Orthopedic Medicine Market Size, Share & Growth Analysis Report, 2030

U.S. Veterinary Orthopedic Medicine Market Growth & Trends

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.    

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

U.S. Veterinary Orthopedic Medicine Market Report Highlights

Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period

Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade

Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period

Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade

On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

U.S. Veterinary Orthopedic Medicine Market Segmentation

Grand View Research has segmented the U.S. veterinary orthopedic medicine market based on product, animal type, application, route of administration, and end-use:

U.S. Veterinary Orthopedic Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)

Biologics

Stem Cells

Platelet-Rich Plasma (PRP)

Other Biologics

Viscosupplements

Pharmaceuticals

Steroids

NSAIDS

Others

U.S. Veterinary Orthopedic Medicine Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

Dogs

Small Breeds

Medium Breeds

Large Breeds

Horses

U.S. Veterinary Orthopedic Medicine Application Outlook (Revenue, USD Million; 2018 - 2030)

Osteoarthritis

Degenerative Joint Disease

Others

U.S. Veterinary Orthopedic Medicine Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Injectable

Intra-Muscular

Intra-Articular

Others

Oral

Others

U.S. Veterinary Orthopedic Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)

Veterinary Hospitals & Clinics

At-home

Others

List of Key Players in the U.S. Veterinary Orthopedic Medicine Market

Zoetis Services LLC

Ardent Animal Health, LLC

Enso Discoveries

VetStem, Inc.

Contura Vet

PetVivo Holdings, Inc.

T-Cyte Therepeutics

Boehringer Ingelheim International GmbH

Arthrex, Inc.

MEDREGO LLC

Nucleus ProVets

Daiichi Sankyo Company, Limited 

Bimeda U.S.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

[bharat059]

Contract Logistics Market 2023-2031 Increasing Demand With SWOT Analysis and Growth Strategies by Top Companies

Contract Logistics Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries covers and analyzes the potential of the global Contract Logistics industry, providing statistical information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy Analysis, opportunities and forecasts. The biggest highlight of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19. At the same time, this report analyzed the market of leading 20 countries and introduce the market potential of these countries. “Contract Logistics market was estimated at USD 282542.93 million, and it’s anticipated to reach USD 425815.91 million in 2031, with a CAGR of 4.66% during the forecast years.”

Get a Sample Copy of the Report at –

Segment by Type

Outsourcing

Insourcing

Which growth factors drives the Contract Logistics market growth?

Increasing use of is expected to drive the growth of the Contract Logistics Market.

Segment by Application

Aerospace

Automotive

High-Tech

Pharma & Healthcare

Retail

Others

Market Segment by Region/Country Including: -

North America (United States, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain, etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Southeast Asia, etc.)

South America (Brazil, Argentina, Colombia, etc.)

Middle East & Africa (South Africa, UAE, Saudi Arabia, etc.)

For More Related Reports Click Here :

Premium Pram and Baby Stroller Market Share

Ionomer for Construction Industry Growth Report

Gastrointestinal Stent Market Statistics

Work Stress Management Industry Forecast

Stabilizers Used in Antibody Drugs and Vaccines Market Size

Vehicle Retarder Market Share

Medical Billing Outsourcing Market

Hearing Protection Devices Market Trends

Spherical Silica Powder Industry Size

Anionic Dispersants Market Forecast

Burn Treatment Anti-Infectives Products Market Forecast

Semiconductor Packaging And Assembly Equipment Market Revenue

Polybutylene Terephthalate (PBT) Industry Forecast

Electric Vehicles Fuel Cell Industry Growth

Biopharmaceutical CMO and CRO Market Share

Soft Exoskeleton (Exosuits) and Wearable Robots Market Trends

Biopharmaceutical CMO and CRO Market Share

Electronics Adhesives Market Trends

Premium Motorcycle Helmet Market Trends

Microplate Reader Market Trends

[yessadirichards]

HealthPositive trial results for RSV infant treatment: Sanofi

PARIS

French pharmaceutical giant Sanofi has announced trial results that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalised by more than 80 percent.

The virus infects around nine out of 10 children by the age of two and is the most common cause of bronchiolitis, a respiratory infection that is normally mild but in some cases can make infants seriously ill.

Sanofi and British-Swedish firm AstraZeneca, which jointly developed the drug nirsevimab, marketed as Beyfortus, say it is the first treatment to prevent severe illness from RSV in infants.

The phase three trial used real-world data from the 2022-2023 RSV season and involved more than 8,000 infants under 12 months across France, Germany and the UK, Sanofi said in a statement.

The results showed an 83 percent reduction in hospitalisations for infants with RSV-related illnesses who received a single dose of nirsevimab, compared to a control group who did not receive the treatment.

The results suggest that "the overall burden on healthcare systems could be reduced significantly if all infants receive nirsevimab," Sanofi said.

Global medical costs worldwide were estimated to be 4.8 billion euros ($5.2 billion) in 2017, it added.

While not a vaccine, nirsevimab is a monoclonal antibody treatment that has a similar aim: to give protection against RSV with a single injection.

More attention has been paid to RSV since a combination of the virus, Covid-19 and influenza dubbed a "tripledemic" put pressure on hospitals in several countries during the northern hemisphere's last winter.

Peter Openshaw, a specialist in lung immunology at Imperial College London, pointed out that the trial data was collected when RSV was rebounding after a dip in cases during Covid lockdowns.

The data "adds to the evidence that use of long-acting monoclonal antibody may prevent moderate to severe RSV disease after a convenient single dose," he said, adding that further studies were needed for older children.

"The cost of nirsevimab will be a critical determinant of how widespread its use can be," Openshaw said.

The drug has already been approved in the European Union, the UK and Canada, and an application in the United States is under review.

Several major pharmaceutical firms have developed vaccines for RSV in adults, and are currently racing to get them approved.

Last week, the US became the first country to approve an RSV vaccine, giving the greenlight to GSK's Arexvy for adults aged 60 or older.

[conceptodiagnostics]

3 Benefits of Corporate Covid-19 Testing

Coronavirus is a respiratory disease brought about by SARS-CoV-2. Most patients contaminated with Covid report gentle to direct side effects and recuperate with the Private Pathology Laboratory in the UK. Nonetheless, patients with previous medical conditions like hypertension, disease, and diabetes might encounter unfavorable impacts. In any case, note that anybody can get the infection, become sick or even kick the bucket, no matter what their age.

 When can you use Corporate Covid-19 testing?

You ought to get tired or Book a Covid-19 Travel Test from the Clinic of the UK, assuming you experience any side effects of Coronavirus, regardless of whether you have gotten every one of the essential antibodies.

Note that Covid spreads rapidly and effectively, even before seeing any side effects. Thusly, the sooner you know whether you have the infection, the better since you can detach it and lessen the possibility of spreading it to other people.

Once in a while you might test negative for the infection yet feel unwell, demonstrating a bogus negative. In such a situation, you ought to disengage and contact your primary care physician to examine your side effects. Nonetheless, assuming you test positive, you should promptly detach and contact your Private Blood Tests Clinic in the UK to begin the treatment plan.

According to Diagnostic Centre in UK, you ought to do a test following five to seven days on the off chance that you are immunized against the infection. Furthermore, if you're not immunized, you ought to get a test. Given below are the 3 Benefits of Corporate Covid-19 testing:

1.    Ensures Successful Detachment

There are various difficulties confronting the battle against the spread of Covid. Luckily, medical services suppliers can utilize fast testing from the Corporate Coronavirus Testing of the UK to analyze whatever number of Coronavirus cases would be prudent before the infection spreads to the more extensive populace.

2.    Simple to Utilize

You don't need to be a clinical expert to do a quick Coronavirus test. You can do it with your family utilizing a home Coronavirus test pack.

3.    Mitigates Financial Effect

With fast testing, people presented with the infection accept their test results within a couple of hours, implying that they don't need to disengage for a long time or miss various business days as they hold back to accept their experimental outcomes. For more information visit the Private Pathology Laboratory in the UK.

 It can be concluded that Patients go through analytic tests from the Diagnostic Centre in the UK to affirm the presence of Coronavirus respiratory sickness. At the point when patients test positive for a fast antigen test, they are disengaged and begin treatment right away.

 Also Read: What Is So Fascinating About the Covid-19 Antigen LFT Test?

[prabha194]

Small Molecule Drug Discovery Market Size, Share, and Global Analysis 2027

According to the latest study on “Small Molecule Drug Discovery Market Forecast to 2027– COVID-19 Impact and Global Analysis by Therapeutic Area, and Process/Phase,” the global small molecule drug discovery market was valued at US$ 24,976.14 million in 2019 and is projected to reach US$ 50,823.06 million by 2027; it is expected to grow at a CAGR of 9.5% during 2020–2027. The report highlights trends prevailing in the global small molecule drug discovery market and the factors driving market along with those that act as hindrances.

Small molecule drugs are used in targeted drug delivery in which small molecules pass through the cell membrane and acts on the specific cellular organelle or protein. The small molecule drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form, and cost-effectiveness.

Market leaders operating in the market have undertaken various organic growth strategies in the small molecule drug discovery Market. The small molecule drug discovery market majorly consists of the players such as Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, GlaxoSmithKline Plc, AstraZeneca, Johnson & Johnson Services, Inc., TEVA PHARMACEUTICAL INDUSTRIES LTD, Boehringer Ingelheim International GmbH, and Allergan Plc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.

Request for sample copy @ https://www.theinsightpartners.com/sample/TIPRE00004774/

The report segmentation of Small Molecule Drug Discovery Market as follows:

Based on process/phase, the global small molecule drug discovery market is segmented into target discovery, target validation, lead generation and refinement, and preclinical development. The lead generation and refinement segment held the largest share of the global small molecule drug discovery market in 2019. However, the target discovery is anticipated to register the highest CAGR during the forecast period. The target discovery segment is expected to grow owing to increasing demand of therapeutics, increasing product approvals, and rising investment in the drug discovery process.

Below is the list of the growth strategies done by the players operating in the small molecule drug discovery market:

In Jan-20 Merck KGaa entered into exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., and Astex Pharmaceuticals, a UK based company. This partnership aims to improve small-molecule inhibitors toward several drug targets, such as KRAS oncogene, and others which are currently under-investigated for the treatment of cancer.

In Dec-19 AstraZeneca linked up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve the productivity of its automated compound synthesis operations. AstraZeneca aims to use DeepMatter's platform to replay and explore its chemical synthesis reactions digitally and to uncover methods to save time and resources as it builds single compounds or larger libraries.

In Jul-19 Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered a strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

Phone: +1-646-491-9876 Press Release: https://www.theinsightpartners.com/pr/small-molecule-drug-discovery-market

[covid-safer-hotties]

Patients With Long-COVID Show Abnormal Lung Perfusion Despite Normal CT Scans - Published Sept 12, 2024

VIENNA — Some patients who had mild COVID-19 infection during the first wave of the pandemic and continued to experience postinfection symptoms for at least 12 months after infection present abnormal perfusion despite showing normal CT scans. Researchers at the European Respiratory Society (ERS) 2024 International Congress called for more research to be done in this space to understand the underlying mechanism of the abnormalities observed and to find possible treatment options for this cohort of patients.

Laura Price, MD, PhD, a consultant respiratory physician at Royal Brompton Hospital and an honorary clinical senior lecturer at Imperial College London, London, told Medscape Medical News that this cohort of patients shows symptoms that seem to correlate with a pulmonary microangiopathy phenotype.

"Our clinics in the UK and around the world are full of people with long-COVID, persisting breathlessness, and fatigue. But it has been hard for people to put the finger on why patients experience these symptoms still," Timothy Hinks, associate professor and Wellcome Trust Career Development fellow at the Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre senior research fellow, and honorary consultant at Oxford Special Airway Service at Oxford University Hospitals, England, who was not involved in the study, told Medscape Medical News.

The Study Researchers at Imperial College London recruited 41 patients who experienced persistent post-COVID-19 infection symptoms, such as breathlessness and fatigue, but normal CT scans after a mild COVID-19 infection that did not require hospitalization. Those with pulmonary emboli or interstitial lung disease were excluded. The cohort was predominantly female (87.8%) and nonsmokers (85%), with a mean age of 44.7 years. They were assessed over 1 year after the initial infection.

Exercise intolerance was the predominant symptom, affecting 95.1% of the group. A significant proportion (46.3%) presented with myopericarditis, while a smaller subset (n = 5) exhibited dysautonomia. Echocardiography did not reveal pulmonary hypertension. Laboratory findings showed elevated angiotensin-converting enzyme and antiphospholipid antibodies. "These patients are young, female, nonsmokers, and previously healthy. This is not what you would expect to see," Price said. Baseline pulmonary function tests showed preserved spirometry with forced expiratory volume in 1 second and forced vital capacity above 100% predicted. However, diffusion capacity was impaired, with a mean diffusing capacity of the lungs for carbon monoxide (DLCO) of 74.7%. The carbon monoxide transfer coefficient (KCO) and alveolar volume were also mildly reduced. Oxygen saturation was within normal limits.

These abnormalities were through advanced imaging techniques like dual-energy CT scans and ventilation-perfusion scans. These tests revealed a non-segmental and "patchy" perfusion abnormality in the upper lungs, suggesting that the problem was vascular, Price explained.

Cardiopulmonary exercise testing revealed further abnormalities in 41% of patients. Peak oxygen uptake was slightly reduced, and a significant proportion of patients showed elevated alveolar-arterial gradient and dead space ventilation during peak exercise, suggesting a ventilation-perfusion mismatch.

Over time, there was a statistically significant improvement in DLCO, from 70.4% to 74.4%, suggesting some degree of recovery in lung function. However, DLCO values did not return to normal. The KCO also improved from 71.9% to 74.4%, though this change did not reach statistical significance. Most patients (n = 26) were treated with apixaban, potentially contributing to the observed improvement in gas transfer parameters, Price said.

The researchers identified a distinct phenotype of patients with persistent post-COVID-19 infection symptoms characterized by abnormal lung perfusion and reduced gas diffusion capacity, even when CT scans appear normal. Price explains that this pulmonary microangiopathy may explain the persistent symptoms. However, questions remain about the underlying mechanisms, potential treatments, and long-term outcomes for this patient population.

Causes and Treatments Remain a Mystery Previous studies have suggested that COVID-19 causes endothelial dysfunction, which could affect the small blood vessels in the lungs. Other viral infections, such as HIV, have also been shown to cause endothelial dysfunction. However, researchers don't fully understand how this process plays out in patients with COVID-19.

"It is possible these patients have had inflammation insults that have damaged the pulmonary vascular endothelium, which predisposes them to either clotting at a microscopic level or ongoing inflammation," said Hinks.

Some patients (10 out of 41) in the cohort studied by the Imperial College London's researchers presented with Raynaud syndrome, which might suggest a physiological link, Hinks explains. "Raynaud's is a condition of vascular control or dysregulation, and potentially, there could be a common factor contributing to both breathlessness and Raynaud's."

He said there is an encouraging signal that these patients improve over time, but their recovery might be more complex and lengthy than for other patients. "This cohort will gradually get better. But it raises questions and gives a point that there is a true physiological deficit in some people with long-COVID."

Price encouraged physicians to look beyond conventional diagnostic tools when visiting a patient whose CT scan looks normal yet experiences fatigue and breathlessness. Not knowing what causes the abnormalities observed in this group of patients makes treatment extremely challenging. "We need more research to understand the treatment implications and long-term impact of these pulmonary vascular abnormalities in patients with long-COVID," Price concluded.

[flashbrosales]

The National Lottery EuroMillions draw results from Friday 17 September 2021

The National Lottery EuroMillions draw results from Friday 17 September 2021

The National Lottery EuroMillions draws take place in front of an independent adjudicator. Rules and Procedures apply (and Account Terms if playing online). Players must be 18+ and physically located in the UK or IoM. To enter the next available draw, visit http://bit.ly/PlayEMs You can also check your EuroMillions tickets on our website: http://bit.ly/EuroMillionsCheckResults Dream Big Play…

[kwttoday]

Early tests show Omicron to be unhindered by majority antibody treatments

Early tests show Omicron to be unhindered by majority antibody treatments

Early tests show Omicron to be unhindered by majority antibody treatments Amid an explosive surge of Covid19 cases around the world majorly caused by the highly transmissible Omicron variant, studies show that antibody treatments that were effective against the previous coronavirus strains may not be effective against the new variant. Dr. Tyler Dougherty with South College School of Pharmacy…

[harpianews]

In a first: UK approves treatment of acute COVID with synthetic antibodies

In a first: UK approves treatment of acute COVID with synthetic antibodies

The United Kingdom’s drug regulator approved the treatment of severe COVID-19 cases using artificial antibodies for the first time in the country, shortly after Texas, Florida and Australia approved similar treatments. The Medicines and Healthcare products Regulatory Agency approved Ronapreve, a drug developed by Regeneron and Roche, that is administered by either injection or infusion and acts…

[yessadirichards]

HealthPositive trial results for RSV infant treatment: Sanofi

PARIS

French pharmaceutical giant Sanofi has announced trial results that showed its preventative treatment for respiratory syncytial virus (RSV) reduced the rate of babies being hospitalised by more than 80 percent.

The virus infects around nine out of 10 children by the age of two and is the most common cause of bronchiolitis, a respiratory infection that is normally mild but in some cases can make infants seriously ill.

Sanofi and British-Swedish firm AstraZeneca, which jointly developed the drug nirsevimab, marketed as Beyfortus, say it is the first treatment to prevent severe illness from RSV in infants.

The phase three trial used real-world data from the 2022-2023 RSV season and involved more than 8,000 infants under 12 months across France, Germany and the UK, Sanofi said in a statement.

The results showed an 83 percent reduction in hospitalisations for infants with RSV-related illnesses who received a single dose of nirsevimab, compared to a control group who did not receive the treatment.

The results suggest that "the overall burden on healthcare systems could be reduced significantly if all infants receive nirsevimab," Sanofi said.

Global medical costs worldwide were estimated to be 4.8 billion euros ($5.2 billion) in 2017, it added.

While not a vaccine, nirsevimab is a monoclonal antibody treatment that has a similar aim: to give protection against RSV with a single injection.

More attention has been paid to RSV since a combination of the virus, Covid-19 and influenza dubbed a "tripledemic" put pressure on hospitals in several countries during the northern hemisphere's last winter.

Peter Openshaw, a specialist in lung immunology at Imperial College London, pointed out that the trial data was collected when RSV was rebounding after a dip in cases during Covid lockdowns.

The data "adds to the evidence that use of long-acting monoclonal antibody may prevent moderate to severe RSV disease after a convenient single dose," he said, adding that further studies were needed for older children.

"The cost of nirsevimab will be a critical determinant of how widespread its use can be," Openshaw said.

The drug has already been approved in the European Union, the UK and Canada, and an application in the United States is under review.

Several major pharmaceutical firms have developed vaccines for RSV in adults, and are currently racing to get them approved.

Last week, the US became the first country to approve an RSV vaccine, giving the greenlight to GSK's Arexvy for adults aged 60 or older.

[paincauses]

Available Treatment Options for Omicron

Omicron is a new variant of the novel coronavirus. The coronavirus is believed to have been synthetically made by human effort and the virus escaped in the human vicinity due to negligence and improper handling of the micro-body at a lab. Since the virus is believed to have been artificially created, the original virus has already produced numerous variants of itself. The novel coronavirus is an RNA-based virus thus it is getting sort of challenging for the researchers to find a permanent solution towards completely eradicating the virus and its variants present and spreading. The virus with the help of its RNA protein produces a new variant to counter every possible vaccine or any drug present and applied.

Severity of Omicron

Though there are many variants of the coronavirus already present in the environment with each one having a different rate of infectivity and a different rate of spreading. This new variant, Omicron, has shown to be much more infectious and has a higher rate of spreading than any other variant present and known to humans. The “rate of spread” is believed to 4 times more than any random variant available. This improves the level of being contagion. This variant is making children, especially those in the adolescent age, more open to the threat of being infected and even being hospitalized. This variant has been declared to be a “variant of concern”.

Spread of the variant virus

Since the rate of spreading for this virus has been determined to be 4 times more than the regular virus or even if compared to any other variant, it has become a reason behind yet another wave of the virus. This virus spreads via droplets, sneezing, coughing, etc. Via contact touching anything that has been contaminated. The virus can spread either directly or indirectly to people.

Symptoms of the infection

A person once getting infected does not show immediate symptoms of the sickness there is a general time gap for the virus to weaken the immune system and attack the health of the person. However, some of the common and most recognizable symptoms of the virus’s infection are:

Sickness and fever

Any person having the virus will have frequent fever, dizziness, and have severe headaches. There may also be cases of shivering and becoming nauseous.

Respiratory symptoms

The person after being infected and having a fever would feel a shortage of breath and also face difficulty in breathing. This happens due to the accumulation of mucous in the lungs and the respiratory tract.

Pneumonia

Some people with extreme levels of infection can also show symptoms of having pneumonia. They would feel cold which would be accompanied by shivering and allied fever.

Shivering and fatigue

The symptoms can also be accompanied by extreme shivering and feeling fatigued. This creates weakness in the person.

Treatment of Omicron infection

Getting vaccinated

The most important and effective mode of treating as well as treating the infection is to get the Covid 19 vaccine; the vaccine produces required antibodies to fight against the infectious virus and also improves immunity.

Having Vitamin C rich food and supplements

It is being recommended to include vitamin C in our diet; this vitamin is helpful in preventing the spread of the virus in our body as this makes our immune system and our immunity strong. You can also include vitamin C supplements in your health regimen after consulting with a doctor.

Have required nursing and therapy

Having proper nursing and look after is very essential and effective against mitigating the virus infection. Moreover, having a doctor’s prescribed schedule of medication is also recommended so that further spread and deterioration of conditions can be prevented.

Please never use Ivermectin for Covid, because it is not approved by the FDA. But you can order Ivermectin online to treat parasitic diseases, but required a valid prescription in USA and UK

[maaarine]

Fibromyalgia may be a condition of the immune system not the brain – study (Linda Geddes, The Guardian, July 01 2021)

“Fibromyalgia – a poorly understood condition that causes widespread pain throughout the body and extreme tiredness – may be caused by be an autoimmune response that increases the activity of pain-sensing nerves throughout the body.

The findings, published in the Journal of Clinical Investigation, challenge the widely held view that the condition originates in the brain, and could pave the way for more effective treatments for the millions of people affected.

They could also have implications for patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and “long Covid”. (…)

Similar to many autoimmune conditions, the vast majority of those affected (80%) are women.

Current treatment tends to focus on gentle aerobic exercise, as well as drug and psychological therapies designed to manage pain.

However, these have proven ineffective in most patients and have left behind an enormous unmet clinical need, said Anderson: 

“The widespread paradigm at the moment is that this is a disease that emanates from the brain, and I think our findings suggest that that’s not the case.”

The development of new therapies has also been hampered by a limited scientific understanding of what causes the condition in the first place, but this could change with the discovery that the immune system is involved.

Anderson and his colleagues harvested blood from 44 people with fibromyalgia and injected purified antibodies from each of them into different mice.

The mice rapidly became more sensitive to pressure and cold, and displayed reduced grip strength in their paws.

Animals injected with antibodies from healthy people were unaffected.

Prof Camilla Svensson from the Karolinska Institute in Sweden, who was also involved in the study, said: 

“Antibodies from people with fibromyalgia living in two different countries, the UK and Sweden, gave similar results, which adds enormous strength to our findings.”

The mice recovered once the antibodies had been cleared from their systems, which took a few weeks.

This suggests that therapies such as plasma-exchange, which are designed to reduce antibody levels and are available for other autoimmune disorders, such as myasthenia gravis, may be effective in fibromyalgia patients.

“Establishing that fibromyalgia is an autoimmune disorder will transform how we view the condition and should pave the way for more effective treatments for the millions of people affected,” Anderson said.”

[maximumwobblerbanditdonut]

Coronavirus restrictions may have to be imposed in the aftermath of the COP26 climate conference in Glasgow.

The 26th UN Climate Change Conference will take place in November 2021, at the Scottish Event Campus (SEC) in Glasgow. 🏴󠁧󠁢󠁳󠁣󠁴󠁿

The COP26 climate change conference could cause an increase in Covid ..could 'trigger the need for further restrictions'. Having huge mass events at the moment, “it is risky." 25,000 delegates will descend on the city in a week during 12 days of the summit.

Viruses are always mutating, spawning minor variations that are more effective at spreading infection.

A new ‘Delta Plus’ variant of COVID-19 🦠 could spread more easily than the original Delta, and is currently under investigation in the UK.

To date, studies have suggested the new variant may bind more easily to lung cells and may be resistant to some of the key antibodies used in treatments against Covid.

There is resistance to calls from health leaders for tighter COVID-19 restrictions over winter, despite the rising levels of infections.